L

LegoChem Biosciences Inc
KOSDAQ:141080

Watchlist Manager
LegoChem Biosciences Inc
KOSDAQ:141080
Watchlist
Price: 192 400 KRW 3.66% Market Closed
Market Cap: ₩7T

Operating Margin

-29.6%
Current
Improving
by 75.8%
vs 3-y average of -105.3%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-29.6%
=
Operating Income
₩-47.1B
/
Revenue
₩159.3B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-29.6%
=
Operating Income
₩-47.1B
/
Revenue
₩159.3B

Peer Comparison

Country Company Market Cap Operating
Margin
KR
LegoChem Biosciences Inc
KOSDAQ:141080
6.8T KRW
Loading...
US
PerkinElmer Inc
LSE:0KHE
1.3T USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
238.1B USD
Loading...
US
Danaher Corp
NYSE:DHR
167.3B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
83T KRW
Loading...
CH
Lonza Group AG
SIX:LONN
38.2B CHF
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
40.5B USD
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
276.7B CNY
Loading...
US
Agilent Technologies Inc
NYSE:A
38.4B USD
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
29.1B USD
Loading...
FR
Sartorius Stedim Biotech SA
PAR:DIM
20B EUR
Loading...

Market Distribution

Lower than 89% of companies in Korea
Percentile
11th
Based on 2 615 companies
11th percentile
-29.6%
Low
-163 055.6% — -2.2%
Typical Range
-2.2% — 6.8%
High
6.8% — 22 874.8%
Distribution Statistics
Korea
Min -163 055.6%
30th Percentile -2.2%
Median 2.7%
70th Percentile 6.8%
Max 22 874.8%

LegoChem Biosciences Inc
Glance View

LegoChem Biosciences Inc., rooted in South Korea, is navigating the complex world of pharmaceutical innovation with a focus sharp enough to captivate both scientists and investors. Founded in 2006, the company has honed its expertise particularly in the field of antibody-drug conjugates (ADCs). This novel approach merges the targeting capabilities of antibodies with the cancer-killing prowess of chemotherapy drugs, aiming to deliver high precision in cancer treatment while minimizing side effects. LegoChem conducts meticulous research and development, advancing its proprietary ConjuAll™ technology platform, which enhances the stability and efficacy of ADCs. This dedication to scientific innovation underscores the company's strategy of robust collaboration and partnerships with global pharmaceutical giants, enabling it to leverage complementary expertise and expedite the commercialization of its cutting-edge therapies. LegoChem Biosciences generates revenue primarily through a strategic business model that revolves around licensing agreements and research collaborations with major pharmaceutical players. The company enters into partnerships where it licenses out its advanced drug discovery platforms, receiving upfront payments, milestones based on developmental progress, and royalties upon successful commercialization of its licensed products. These collaborative strategies not only finance ongoing research but also diversify revenue streams and mitigate the inherent financial risks associated with drug development. By focusing on areas with high unmet medical needs, LegoChem not only positions itself advantageously in the competitive biotech landscape but also aligns with a mission to transform lives through innovation. With a clear-eyed vision and strategic partnerships, LegoChem Biosciences Inc. continues its quest to make significant strides in the realm of targeted cancer therapies.

LegoChem Biosciences Inc Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-29.6%
=
Operating Income
₩-47.1B
/
Revenue
₩159.3B
What is LegoChem Biosciences Inc's current Operating Margin?

The current Operating Margin for LegoChem Biosciences Inc is -29.6%, which is above its 3-year median of -105.3%.

How has Operating Margin changed over time?

Over the last 3 years, LegoChem Biosciences Inc’s Operating Margin has increased from -35.1% to -29.6%. During this period, it reached a low of -236.7% on Dec 31, 2023 and a high of -8.5% on Mar 31, 2025.

Back to Top